Holen Sie sich die Stockscreener-App
17.34
0.12%
-0.02
Schlusskurs vom Vortag:
$17.36
Offen:
$17.26
24-Stunden-Volumen:
1.34M
Relative Volume:
0.69
Marktkapitalisierung:
$2.64B
Einnahmen:
$205.22M
Nettoeinkommen (Verlust:
$-121.24M
KGV:
-21.30
EPS:
-0.8141
Netto-Cashflow:
$-82.81M
1W Leistung:
+1.29%
1M Leistung:
+20.58%
6M Leistung:
+76.22%
1J Leistung:
+226.55%
1-Tages-Spanne:
$17.00
$17.52
1-Wochen-Bereich:
$16.59
$17.76
52-Wochen-Spanne:
$4.27
$17.89
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Vergleichen Sie ADPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
17.34 | 2.64B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Can technical indicators confirm Adaptive Biotechnologies Corporation’s reversal2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
How Adaptive Biotechnologies Corporation stock compares to industry benchmarksMarket Trend Report & Community Verified Watchlist Alerts - newser.com
Will Adaptive Biotechnologies Corporation (1HM) stock sustain uptrend momentumGap Down & Free Long-Term Investment Growth Plans - newser.com
Can Adaptive Biotechnologies Corporation (1HM) stock expand revenue streams2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Why Adaptive Biotechnologies Corporation stock could benefit from AI revolutionJuly 2025 Setups & Verified Swing Trading Watchlists - newser.com
Using Ichimoku Cloud for Adaptive Biotechnologies Corporation technicalsWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
What catalysts could drive Adaptive Biotechnologies Corporation stock higherTake Profit & Daily Profit Focused Stock Screening - newser.com
How New Developments Are Shaping Analyst Views on Adaptive Biotechnologies’ Future - Yahoo! Finance Canada
How Adaptive Biotechnologies Corporation stock reacts to oil pricesJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
How Adaptive Biotechnologies Corporation stock performs in high volatility marketsPortfolio Performance Report & Consistent Return Investment Signals - newser.com
Does Adaptive Biotechnologies Corporation fit your quant trading modelPortfolio Gains Summary & Reliable Intraday Trade Alerts - newser.com
Cwm LLC Sells 1,487 Shares of Adaptive Biotechnologies Corporation $ADPT - Defense World
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
How Adaptive Biotechnologies Corporation stock trades during market volatilityTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Adaptive Biotechnologies2025 Funding Rounds & List of Investors - Tracxn
Adaptive Biotechnologies (ADPT) Price Target Increased by 17.35% to 16.76 - Nasdaq
What dividend safety score for Adaptive Biotechnologies Corporation stockJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Technical signs of recovery in Adaptive Biotechnologies Corporation2025 Market Trends & Verified Entry Point Detection - newser.com
Is Adaptive Biotechnologies Corporation stock supported by innovation pipelineGap Down & Comprehensive Market Scan Insights - newser.com
Heatmap analysis for Adaptive Biotechnologies Corporation and competitorsBuy Signal & Expert Approved Trade Ideas - newser.com
Is Adaptive Biotechnologies Corporation stock a contrarian buyBear Alert & Community Consensus Picks - newser.com
How Adaptive Biotechnologies Corporation (1HM) stock performs during market turbulenceTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
Will Adaptive Biotechnologies Corporation stock benefit from upcoming earnings reportsPortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Exit strategy if you’re trapped in Adaptive Biotechnologies CorporationPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):